Heather Deehan

Engagement with the Government regarding the Life Science Fund seeking partnership and funding to support completion of Phase I and Phase II clinical research program associated to AMR (antimicrobial resistance) Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Also discuss any applicable conditions regarding this funding. Programs and policy to support Canadian biomanufacturing and access to medicines and vaccines for Canadians. National Immunization Strategy and policies and programs that impact public access to vaccines and disease prevention in Canada. Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy and policies and programming related to biomanufacturing in Canada Access to medicines - government policies, processes, legislation, and/or regulation with potential impact on access to medicines in Canada. Trade-related matters, including policies and tariffs impacting medicines and vaccines. Policies and programs related to the health of new immigrants to Canada. Policies, programs, and funding related to Canada's Sexually Transmitted and Blood-Borne Infections (STBBI) Action Plan 2024-2030. Engagement with federal officials regarding Health Emergency Readiness Canada. The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004. Advocacy for ways to increase access to medicines and vaccines for Canadian patients. The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada. Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR. Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage. Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts. Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework. Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment. Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development. Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice. Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process. Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions. FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario Engage with government to strengthen the Priority Review for Drug Submissions process. Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians. Engagement with the Government regarding the Strategic Innovation Fund Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply fo

Regulatory approval process, in respect to the egg supply management system Agriculture as a strategic priority, in respect to economic growth and tools to support the agriculture sector and support food security. Policy on Salmonella Enteritidis in Canadian shell eggs, in respect of on-farm testing and vaccination pilot program Availability of animal health products and tools, in respect to disease response and preparedness in Canada Agriculture inputs into egg supply chain, in respect to pricing and availability for farmers Sustainability initiatives as they relate to agriculture, including emissions reduction programs and on-farm green transition Trade policy, in respect of supply management and international and domestic trade Programming to mitigate the market impacts caused by trade agreements Private sector risk management program, in respect of insurance Growing forward, in respect of suite of business risk management and supply management Egg regulations, in respect to egg grades, weights and labelling Consumer Packaging and Labelling Regulations with respect to production claims on labels Canadian Food Inspection Agency On-Farm Food Safety Recognition Program, in respect to program development for pre-lay sectors Agriculture international development projects, in respect to supporting vulnerable communities and empowering egg farmers around the world

Discuss increasing incidents of violence against health care workers, prevention, and enforcement of existing laws. Support nursing students through targeted financial support such as paid preceptorships and federal grants. Support internationally educated nurses through establishing a collaborative, multi-stakeholder body hosted by Health Canada, to lead national strategy, planning and coordination for internationally educated nurses' registration, integration and support. Targeted funding of $1 billion as an initial investment to immediately begin to address the current health care workforce crisis experienced by provinces/territories across Canada, with funding focused on short and long-term goals. To achieve patient-centred quality care based on the WHO’s comprehensive health labour markets framework that would be acceptable to, and delivered by, the provinces/territories. Provide sustainable funding so nurses and other healthcare workers have access to mental health supports. In keeping with the recommendations of the Truth and Reconciliation Commission, establish specific targets and timelines for the admission and graduation of First Nations, Métis and Inuit health professionals in all postsecondary institutions and provide funding dedicated to indigenous nurse students. Implementing a Universal single-payer pharmacare program. Fund innovative retention and recruitment programs targeted at early-career, mid-career and late-career nurses. Establish a dedicated coordinating body to address critical health workforce data gaps based on global best practices on health workforce management. Address health workforce shortages through the implementation of a comprehensive, pan-Canadian health human resources strategy, in coordination with the provinces and territories, backed by sufficient funding and with real accountability for achieving desired health outcomes; and address critical data gaps through significantly enhancing existing health workforce data infrastructure to standardize data collection and analysis across workers, sectors and jurisdictions, with links to relevant patient information, healthcare utilization and outcome data, for more fit-for-purpose planning and tools available at the provincial, territorial, regional and training program level. In designing this, Canada should draw on global best practices in health workforce planning including in Australia and New Zealand.

Raise awareness of the company HIPRA and its plans to expand in Canada to support routine and pandemic vaccination programs.

Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance. National Strategy for Drugs for Rare Disease as it relates to separate regulatory pathways for drugs for rare diseases and the government strategy. Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED). Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework. Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries Policies related to the National Strategy for Drugs for Rare Disease as it relates to separate regulatory pathway for drugs for rare diseases and the government strategy. Policies related to Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors; Information and Submission requirements for SEBs, regulations and intellectual property policies, naming conventions Monitoring and engaging on the Government’s commitment (Budget, SFT, Fall Economic Update) to create a national strategy for drugs for rare diseases; create a new Canadian Drug Agency; and the implementation of national, universal pharmacare. Pharmaceutical policy and any negotiations of a Health Accord or agreement with the Provinces/Territories, as it relates to National Pharmacare/universal or catastrophic drug coverage, Drug policies & Pricing. The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy National Pharmacare (Bill C-64, An Act respecting pharmacare) Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies. Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products. Income Tax Act as it relates to biopharmaceutical industry. Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy. Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver - Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". The Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of importation legislation in the United States. Standing Committee on Finance (FINA) as it relates to pre-budget consultations. Pharmaceutical intellectual property protection as it relates to international trade agreements Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property, approval for therapeutic products, changes to modernize the Right of Appeal House of Commons Standing Committee of Science and Research (SRSR) as it relates to Science in Canada and/or any other pertinent legislative proposal before the committee House of Commons Standing Committee of Industry and Technology (INDU) as it

The government’s Pandemic Preparedness Strategy as it relates to the corporation’s future operations in Canada Health Canada and Public Services and Procurement Canada policies regarding the development, procurement, and distribution of Moderna’s COVID-19 vaccine to various segments of the population, including future distribution models Government policies regarding innovation, research and development, and messenger ribonucleic acid (mRNA) biotechnology